Nkarta appoints Shawn Rose as CMO & Head of R&D; David Shook resigns effective June 6

Nkarta, Inc.

Shawn Rose, M.D. Ph.D, joins as CMO and Head of R&D starting June 23, 2025, succeeding David Shook.
Dr. Shook resigned to pursue other oncology opportunities; will consult through July 11.
Dr. Rose brings experience from Vividion, Magenta, Janssen, and BMS, with work on Sotyktu, Stelara, Tremfya.
Company reaffirms focus on allogeneic NK cell therapies for autoimmune disease.
Annual meeting results: all three Class II director nominees elected; Ernst & Young ratified as auditor.

item 5.02item 5.07item 7.01item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

David Shook

Chief Medical Officer and Head of Research & Development

NKTX · Nkarta, Inc.

Effective: 2025-06-06
Successor: Shawn Rose, M.D. Ph.D.
Filed: Jun 06, 2025 23:59 UTC

David Shook, M.D. notified Nkarta, Inc. (the “Company”) of his decision to resign as Chief Medical Officer and Head of Research & Development of the Company to pursue other opportunities in the oncology space.

Appointed

Shawn Rose

Chief Medical Officer and Head of Research and Development

NKTX · Nkarta, Inc.

Effective: 2025-06-23
Filed: Jun 06, 2025 23:59 UTC

Shawn Rose, M.D. Ph.D. has been appointed by the Company to succeed Dr. Shook as Chief Medical Officer and Head of Research and Development starting on June 23, 2025.

Source: SEC EDGAR

accession 0000950170-25-082717

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.